Abstract: An emulsion contains A) an alkyl ester quat of formula I wherein R1 is an acyl radical of a fatty acid with a chain length of from 6 to 24 carbon atoms, with the proviso that a mass fraction of saturated, linear fatty acids with a chain length of from 12 to 24 carbon atoms, is more than 50% by weight, based on all acyl radicals R1, wherein R2 is an alkyl radical having 1 to 6 carbon atoms, wherein a=1-3 and b=1-3, with the proviso that a+b=4, B) at least one consistency regulator, and C) at least one cosmetic oil.

Abstract: The present invention is directed to a class of mixed polyglyceryl polyester quats that provide multifunctional benefit in personal care applications, including but not limited to (1) conditioning, (2) antistatic properties, (3) bacteriostatic properties and (4) exceptional mildness to skin and eyes. The products are made by the reaction reacting some on the many hydroxyl groups present on polyglycerin with (1) with fatty acids, then (2) diacids then reacted with epoxy cationic compounds to make film forming cationic polymers that are bacteriostatic and of interest in inhibiting biofilm formation on environmental surfaces.

Abstract: This disclosure relates to amphiphilic compounds containing a cyclobutene or cyclobutane moiety. In some embodiments, the compounds are useful for treating infection by Mycobacterium such as Mycobacterium tuberculosis. Cyclobutene containing compounds are also useful as monomers in the preparation of amphiphilic polymers.

Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

Abstract: Rich tooling is provided for REST application development that integrates the exploration of a REST API, modeling of data types and the REST API, and the generation of artifacts using the modeled REST API and data types.

Abstract: The present invention relates to omegabalins, which are GABA derivatives of omega-3 fatty acids, and their use in pharmaceutically-acceptable formulations for treating neuropathic pain, fibromyalgia, epilepsy, anxiety, depression, insomnia, Alzheimer's disease, and other neurological conditions.

Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

Abstract: A metal-air battery comprising a two phase electrolyte system is provided. The two phase electrolyte system contains an aqueous phase and an ionic liquid phase wherein an amount of water exceeds the aqueous solubility of the ionic liquid. In one embodiment the metal-air battery is a lithium-air battery.

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological degenerative disorders, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Alzheimer's disease, Lewy body disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.

Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.

Abstract: The present invention relates to cosmetic and/or personal care formulations and/or compounds. In one embodiment, the present invention relates to ester compounds that can be used in various personal care formulations and/or compounds. In another embodiment, the present invention relates to branced ester compounds having a molecular weight of at least about 1,500 daltons that can be used in various personal care formulations and/or compounds.

Abstract: Cosmetic formulations including specific ester quats based on isopropanolamine are provided, as well as the use of these ester quats in cosmetics.

Abstract: Chemically-modified fatty acids are prepared by reacting epoxidized fatty acids, their esters or triglyceride oils with amines of cyclic or aromatic hydrocarbons. The fatty acid derivatives produced are of the formula: wherein R is an H, branched or straight chain alkyl or alkenyl group, aromatic-containing group, glycerol, or glyceride, R? is a C3 to C29 aliphatic chain comprising one or more of the derivatized methylene groups of the formula: wherein R1 and R2 are independently selected from the group consisting of H, cyclic hydrocarbons, substituted cyclic hydrocarbons, and aryl groups, with the proviso that only one of said R1 and R2 may be H. These fatty acid derivatives have utility as antiwear/antifriction additives for industrial oils and automotive applications.

Abstract: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

Abstract: Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.

Abstract: This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis.

Abstract: The invention relates to a method for removing an organic compound having one or more positive charges from an aqueous solution. Said method consists of the following steps a) the aqueous solution containing the organic compound, and a hydrophobic organic solution which contains a hydrophobic liquid cation exchanger having one or more negative charges and a negative total charge, are provided, b) the aqueous solution and the organic solution are brought into contact with each other and c) the organic solution is separated from the aqueous solution.

Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.

Abstract: The present invention relates to a method of preparing a fabric softener and to a fabric softener prepared thereby, and more particularly, to a method of preparing a fabric softener containing an esterquat by performing a two-step transesterification reaction on oil and tertiary hydroxyalkyl amine at a low temperature in a high vacuum state under specific conditions, and then quaternizing the resultant product. The method of preparing a fabric softener containing an esterquat according to the present invention can reduce the content of unconverted glyceride, glyceryl ester, or a mixture thereof, and can provide a fabric softener with excellent long-term stability.

Abstract: A lipid particle can include a cationic lipid. Synthesis of the cationic lipid can include a ylide-based reaction, such as a Wittig reaction or sulfur ylide reaction. In some cases, the synthesis can also include a Michael addition or a related addition reaction.

Abstract: The invention relates to novel quaternary ammonium compounds of the esterquat type, to a method for the production thereof, and to the use thereof in formulations.

Abstract: The invention relates to novel quaternary ammonium compounds of the esterquat type, to a method for the production thereof, and to the use thereof in formulations.

Abstract: A composition comprising an esterquat that is a quaternized reaction product of an alkanol amine and a fatty acid having a ratio of fatty acid to alkanol amine of 1.5 to 1.75, wherein 45 to 75% by weight of the fatty acids are saturated. Also, a method of softening a fabric and increasing fragrance delivery comprising treating the fabric with the composition.

Abstract: Amine-initiated polyether polyols are made by reacting an amine adduct with a triglyceride in the presence of an alkylene oxide to obtain a polyol having a total renewables content of at least 20%.

Abstract: Here described are compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.

Abstract: Described herein are nitrated lipids and methods of making and using the nitrated lipids.

Abstract: A composition and processes for the reduction of the tendency to baking, moisture absorption and/or dust formation of a granulate being susceptible therefore, such as fertilizers, minerals, ores, as well as to obtain stable coloring dispersions, density control of cokes and the reduction of foam in industrial processes, wherein synthetic polymers of fatty alkyl compounds, especially fatty acid esters and fatty-alcohols, fatty amines, fatty amides and fatty ethers, or distillation residues of the original monomers themselves, can be used, are disclosed. The distillation residues are preferably derived from the bottom fraction, obtained by distillation of the fraction being suitable as biodiesel during the biodiesel production process.

Abstract: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

Abstract: To provide a water-soluble working fluid which less adversely affects the human body and the ecological system as compared with conventional water-soluble working fluids, which has high rotting resistance, and which provides excellent working performance. The water-soluble working fluid of the invention contains methyldicyclohexylamine.

Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alky lhetro cycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).

Abstract: A co-salt of a polyunsaturated fatty acid and a non-fatty acid is formed as a precipitate. The co-salt formed is free flowing and does not tend to agglomerate (cake) in storage. The resultant co-salt product will be easy to blend with other products to produce dietary supplements. These novel co-salt products may also tablet very well and may be added to current dietary supplement tablets.

Abstract: The invention relates to compositions containing one or more compounds of the formula (1), wherein R1CO and R2CO are linear or branched saturated acyl groups independent of each other, having 18 to 24 C atoms, and A? is a counter-ion, and the total amount of C18-23-alkyl COO groups is 40.0 wt.-% or more, based on all groups R1COO— and R2COO—. The compositions are, for example, cosmetic, dermatological, or pharmaceutical compositions.

Abstract: The present invention relates to a method for promoting infant feeding, growth or development comprising administering to an infant a formula or a pharmaceutical composition comprising an endocannabinoid in an amount sufficient to promote feeding, growth or development. The present invention also relates to an infant formula comprising an enhanced amount of an endocannabinoid. The infant formula of the invention may be in a powder form or in a liquid form. The infant formula or the pharmaceutical composition may further comprise an endocannabinoid-promoting compound.

Abstract: A hair growth regulating agent containing, as an active ingredient, a compound represented by the following formula (I): [wherein R1 represents a substituted or unsubstituted, linear or branched C2 to C25 alkyl group; a group represented by the following formula (II): (wherein R1? represents a substituted or unsubstituted, linear or branched C2 to C20 alkylene group, or —(CH2)n-{O—(CH2)m}o-O—(CH2)p- in which each of n, m, o, and p is an integer from 1 to 6; X? represents —CO—NH—, —O—CO—O—, —NH—CO—, —CO—O—, —O—CO—, or —O—; Y? represents a substituted or unsubstituted C1 to C4 alkylene group; R2? represents a hydrogen atom or a C1 to C4 alkyl group; R3? represents a C1 to C4 alkyl group; and when R2? and R3? each represent a C1 to C4 alkyl group, the two alkyl groups may be identical to or different from each other); or a group represented by the following formula (III): (wherein R1?, X?, and Y? have the same meanings as defined above; R4?, R5?, and R6?, which may be identical to or different from one another,

Abstract: An amphiphilic compound is provided capable of forming vesicles or liposomes, said amphiphilic compound having at least one headgroup containing a selectively cleavable group or moiety such as a residue of a choline or phenylalanine derivative, and at least one hydrogen-bonding group located either within said headgroup and/or in close proximity thereto. The cleavable group or moiety is cleaved under selective conditions including change of chemical, physical or biological environment and is preferably cleaved enzymatically in a biological environment such as the brain or the blood. Vesicles or liposomes made from said amphiphilic compounds are suitable for delivery of a therapeutic substance or a diagnostic agent specifically to a target organ or tissue, or for delivery of a nucleic acid for gene therapy.

Abstract: Provided are an ionic liquid and a method of preparing the same. The ionic liquid includes at least one type of compound represented by (Cat+)(R?COO?). Here, the Cat+ is a cation selected from the group consisting of quaternary ammonium, quaternary phosphonium, sulfonium, imidazolium, pyridinium, pyrazolium, piperidinium, pyrrolium, pyrrolidinium, triazolium, and a mixture of two or more thereof, and R? is a hydrocarbon comprising at least one unsaturated bond, and having 4 to 30 carbon atoms. The ionic liquid is partially or completely miscible with various polar and/or non-polar solvents, and may be used as a solvent, a solvent additive, an electrolyte, a heat carrier, a charge carrier, a heat carrier additive, a charge career additive, or a phase transfer catalyst, at room temperatures and below. Furthermore, the cost of manufacturing the ionic liquid can be reduced.

Abstract: Described herein are nitrated lipids and methods of making and using the nitrated lipids.

Abstract: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

Abstract: Crystals comprising (2R)-2-propyloctoic acid and an amine which retain the pharmacological effect of (2R)-2-propyloctoic acid and can be safely used as a medicinal raw drug for peroral solid preparations. Of these crystals, the crystals especially with dibenzylamine are advantageous because not only the crystals themselves are useful as a medicinal raw drug but also use of the crystals as an intermediate can yield (2R)-2-propyloctoic acid having an optical purity exceeding 99.5% e.e., which has not been obtained hitherto.

Abstract: The present invention relates to drugs consisting of unsaturated fatty amino-acid derivatives of the general formula (I), and to their pharmaceutically acceptable acid addition salts, in which: X is oxygen or NH, Rn are independently hydrogen or a (C1-C6)alkyl optionally substituted by halogen; R1 is hydrogen, fluorine, chlorine or bromine, or a CF3 or CHF2 or a (C1-C6)alkyl, (C1-C6)alkenyl or (C1-C6)alkynyl, optionally substituted by one or more halogen atoms; R is hydrogen or a (C1-C6)alkyl or (C3-C6)cycloalkyl optionally substituted by one or more halogen atoms; Ra and Rb are independently hydrogen (C1-C6)alkyl or (C1-C6)acyl, and Ra and Rb a hydrocarbonated cycle containing 4 to 6 carbon atoms; and n is an integer between 2 and 14.

Abstract: The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations.

Abstract: The present invention provides compositions comprising cationic lipids, liposomes and nucleic acid-lipid particles comprising the cationic lipids, and methods of using such compositions, liposomes, and nucleic acid-lipid particles.

Abstract: Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.

Abstract: Preservative systems on the basis of cationic surfactants are known i n the art, a typical example of such cationic surfactants is the ethyl ester of the lauramide of arginine monohydrochloride (LAE) (2). Besides the chloride form the corresponding bromide and sulphate salts are known. It was found that other salts of the cationic surfactants display excellent properties, such as the salts of lactic acid, glutamic acid and acetic acid. It was further found that the combination of the cationic surfactants with at least one salt of an organic or inorganic acid displayed an excellent preservative action. A further preservative system with favourable properties was the combination of the cationic surfactants with at least one ester compound, amide or enzyme inhibitor. Also the combination of the cationic surfactant with a further cationic molecule such as ethyl arginate, glucosamine or chitosan led to an effective preservative system.

Abstract: The present invention relates to methods of improving the low temperature storage and performance properties of fatty acids and/or derivatives thereof, as well as compositions containing fatty acids and/or derivatives thereof having superior lower temperature storage and performance properties.

Abstract: Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.

Abstract: Polyethylene glycol (PEG)-lipid conjugates, polyethylene glycol (PEG)-lipid conjugate based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.

Abstract: Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.

Abstract: Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.